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Foreword 
 
The paper hereby presented is the fourth semester project of the second year of studies at the Nat-
Bas program at Roskilde University. 
The theme for this project is open and could be based either in an experimental work or literature 
research. We consider our project Botulinum toxin immunoresistane in dystonia medical application 
a review paper; that is a combination of the first semester theme (Application of natural science in 
technology and society) and the third semester theme (Reflection of natural science and the 
dissemination of knowledge in the field of natural science).   
 
For the first time in the Nat-Bas studies the semester project should be written as a scientific paper 
intended to be published in a real scientific journal. 
 
We have decided to write a scientific paper that we would like to be published in the journal Toxicon. 
Each scientific journal has its own publication requirements and writing style. In this review paper we 
have tried to follow all the requirements exposed in appendix 1.  
 
The use of Botulinum toxin (BoNT) in medical application is an increasing field of investigation and is 
directly related to: Chemistry, Biochemistry and Medical Biology.  Both Chemistry and Biochemistry 
are subjects that we would like to continue in our studies. Another reason was that the study of this 
toxin in medical application is a relatively new topic. Not everything about this toxin and 
immunoresistance is known and further work is being done in different research centers around the 
world. 
 
We have done our best in order to make this document as close as possible to a real scientific paper. 
The complexity of the content together with the relative newly field of investigation has made quite 
challenging the redaction of a review paper. However we are proud and glad to present you the 
outcome of our work. 
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       ABSTRACT 
 
Botulinum Toxin type A is a protein produced by the bacteria Clostridium botulinum that exists in six 
different serotypes. The ability of this toxin is to inhibit the neurotransmitter acetylcholine at the 
neuromuscular junction and as a consequence of that the muscle signaling will be disrupted. The 
usage of BoNT-A has been considered a good alternative in minimizing the muscle disorders pain and 
posture but without curing the disease.  The treatment with BoNT-A implicates a number of 
numerous injections in order to sustain symptom control and thus makes the patient vulnerable in 
developing neutralizing antibodies that interact against the neurotoxin ability of working. Blocking 
antibodies are the natural defense against the toxin and the complexing proteins present in the BoNT-
A. Three different types of brands, Xeomin, Botox and Dysport are used as treatments for 
improving the life of patience affected by dystonia. The results presented in the review conclude that 
Botox and Dysport contain complexing proteins, whereas Xeomin only contains the active neurotoxin 
and therefore reduce the immunoresistance. This review is a brief summary of the available 
information today, considering the immunoresistance against the BoNT-A in the patients affected by 
Dystonia. 
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1. Introduction  
 
Botulinum neurotoxin (BoNT) is a protein produced by the spores of Clostridium 
Botulinum bacteria. There are seven types of botulinum toxin, where all types are 
toxic in different degrees. BoNT is among the most potent toxins known to man. The 
application and usage of botulinum toxin in medical application have expanded 
dramatically over the last quarter of the century (Eleopra et al.,1998). 
In this review article our intention is to explain the main properties of botulinum 
neurotoxin type A (BoNT-A). Scientists have been studying BoNT molecules to 
understand its structure and mechanism of action. This knowledge has been applied 
for the use in medical applications, mostly in movement related disorders (Truong 
and Jost, 2006). In this review we will briefly explain how BoNT-A can be applied in 
dystonia, a movement disorder associated with Parkinson’s disease. As it is today 
there is no cure for dystonia, the only goal is to reduce the symptoms. Patients, who 
are treated with BoNT-A, are able to control their movement and in some cases it 
also reduces pain (Jankovic, 2009). BoNT is considered as safe to use in medical 
applications, no long term side effect are known. Unfortunately, some patients have 
an immune response to BoNT after being treated with botulinum toxin (Atassi, 
2004). Our intention is to explain the different types of immunoresistance as well as 
what are the possible reasons for the antibodies formation. Additionally, we will 
illustrate the ways to solve this problem. 
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2. BoNT-A chemistry and Dystonia application. 
Chemical structure  
 
Botulinum Toxin (BoNT) from a chemical and structural point of view is a 
protein. In Figure 1 we can see the protein model and the different parts of it. BoNT-
A consists of a heavy amino acid chain with a molecular weight of 100 kDa and a light 
amino acid chain with a molecular weight of 50 kDa (LC). The heavy chain and the 
light chain are interconnected by a single disulfide bond (Oguma et al., 1995). The 
integrity of this disulfide bond is very important for the toxin’s biological activity. 
That is of major interest when talking about the toxic mechanism of the toxin. The 
disulfide bond together with the amino terminal end of the heavy chain is 
responsible for the translocation of the light chain into the cytosol (Sandvig, 2003). 
The heavy chain consists of two domains of ~50KDa each: These are the N-terminal 
domain (Hn) and the C-terminal domain (HC).  
 
 
 
Figure 1. BoTN protein with the different subdomains: Light chain (LC) in red. Heavy chain with two 
sub-functional domains: in purple the C-terminal domain (Hc), and in blue the N-terminal 
translocation domain (HN) (Lacy, et al., 1998). 
 
Each of these two domains has a specific function. The HC domain is responsible of 
binding to the receptors of the pre-synaptic nerve surface. The HN domain is 
responsible for releasing the light chain (Lc) from the endosome into the cytosol of 
the cell. The light chain Lc is responsible of the cleavage and the inactivation of the 
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SNAP-25 (essential component of the neuroexocytosis apparatus). More details 
about BoNT working mechanism in the Toxic action mechanism section. 
 
Table 1. Summary of BoNT protein composition and chemical description.  
 
BoNT Protein 
chains  
Chain domains Chemical description Function 
Heavy chain  HC: C-terminal 
domain 
Termination of the protein 
chain with a free carboxyl 
group 
Binding to the presynaptic-
nerve surface. 
Hn: N-terminal 
domain 
Termination of the protein 
chain with a free amino 
group 
Translocation of the light 
chain inside the cytosol. 
Light chain  Zn-dependent protease Cleavage and inactivation of 
the SNAP-25 
 
The explanation for the chemical interaction and folding of the tertiary structure of 
BoNT protein is long and complex. Here we have explained the basic chemistry of 
the structure. That will help to understand the working mechanism of BoTN 
explained in the next point. 
Toxic action mechanism of BoNT-A 
 
The intoxication process can be divided into four parts. The first two steps are 
called binding and internalization. When the protein is injected directly into the 
muscle it is expected that it will remain 2.5-3 centimeters from the injection area. 
After toxin reaches the target muscle it binds to the cell receptor with a heavy chain. 
It has been shown that synaptic vesicle protein 2 (SV2) is the protein receptor for 
BoNT-A (Dong et al., 2006). After the BoNT protein is bound to the cell surface it 
enters the cell by receptor-mediated endocytosis forming an endosome. (Atassi, 
2004). See Figure 2 for the mechanism of action of BoNT-A.  
Once the toxin is inside the cell, in the endosome, the second step starts; it is 
called pH dependent translocation. The pH in the endosome is lower than the pH in 
the cytosol (Sandvig, 2003). This pH difference makes that some hydrophobic groups 
of the heavy chain becomes accessible. Even though the exactly mechanism is not 
completely understood, it has been proved that the heavy chain, with the accessible 
hydrophobic groups, interacts with the endosome membrane creating some 
“channels” for the release of the light chain. In the endosome membrane the 
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disulfide bond between the heavy chain and the light chain is cleaved permitting the 
light chain to be released into the cell cytosol.  When the light chain separated from 
the BoNT protein complex, the original tertiary structure of the protein is destroyed. 
That means that the light chain is ultimate responsible of the toxic effect of the BoNT 
(Simpson, 2004).  
After LC  separates from the toxin, the final step, called inhibition, starts. The 
light chain cleaves one of the proteins in the SNARE complex. The SNARE complex is 
widely considered to be the catalyst of the membrane fusion and essential for the 
release of neurotransmitter (Montal, 2010). In the motor neurons BoNT-A cleaves 
the SNAP-25 protein, which is the component of the SNARE complex. This complex 
cannot function because the vesicle and the target membrane do not bind together 
and therefore neurotransmitter acetylcholine cannot leave the nerve terminal. Thus, 
muscle contraction is disrupted. Numbers on the picture represent intoxication steps 
that are explained in Figure 2. Number 1 is binding, 2-internalization, 3-translocation 
and that last step 4- inhibition of neurotransmitter release (Turton et al., 2002). 
 
In the following section will focus on Dystonia, giving a general explanation about 
the disease and the symptoms. How BoNT is helping patients with Dystonia will also 
be described.   
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Figure 2.  Mechanism of action of botulinum neurotoxin type A.  1-2.The BoNT protein binds to the 
cell receptors with a heavy chain (HN (green) and Hc (blue). After the protein is bound to the receptors 
it enters the cell by endocytosis. 3. Once the protein is inside the cells pH sensitive tertiary structure 
gets destroyed and the light chain (LC-Yellow) is released to the cytoplasm. 4. LC cleaves the SNARE 
complex protein SNAP-25 to disrupt the release of neurotransmitter acetylcholine. (Turton et.al., 
2002) 
 
Dystonia 
 
Dystonia is a condition that is described by involuntary muscle contractions 
that causes slow repetitive movements or abnormal postures (Fahn et al., 1998) and 
can occasionally be found in rising Parkinson's disease or in association with 
untreated Parkinson disease (Tolosa and Compta, 2006). The beginning of most 
dystonia is unknown, though the researchers believe that there may be 
abnormalities to the basal ganglia and cerebellum or abnormalities to the brain’s 
ability in processing the neurotransmitter dopamine, that help cells in the brain to 
communicate with each other (Neychev et al., 2008). 
Classification of dystonia can be organized as generalized or focal, and can 
occur as a primary syndrome or secondary to another disease. There are about 50 
clinical conditions reported to cause dystonia that may affect only one muscle, 
groups of muscles, or muscles throughout the body. 
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The disorder may be hereditary or caused by other features like birth associated, 
physical damage or adverse reaction to different medicines (e.g. tranquilizing 
psychiatric treatment) (Bertram and Williams, 2012).  
Cervical dystonia is the most common type of dystonia. The muscles in the 
neck that regulates the position of the head are affected, disturbing the head to turn 
to one side or be dragged forward or backward (Albanese et al., 2006). 
Blepharospasm is the second most common focal dystonia appearing involuntary, 
violent affecting the contraction of the muscles controlling eye blinks. The symptoms 
are increasing and uncontrollably blinking while other times the spasm will force the 
eyes to close. Cranio-facial dystonia, oromandibular dystonia and spasmodic 
dysphonia are all describing dystonia that affects the muscles of the head, face and 
neck (Albanese et al., 2011). 
The hereditary reason for dystonia is caused by mutations in the genome. The effect 
starts manifesting in childhood, affecting the limbs and progresses causing major 
disability along the maturity (Calakos et al., 2009). 
An early appearance of dystonia starts at the age of 20-30 years and affects 
different parts of the body provoking different symptoms. Early symptoms can 
include a foot cramp after running some distance; in other occasion it can affect the 
turning of the neck when the individual is tired. The symptoms tend to remain 
localized with restricted progression to nearby muscles. 
By regions of the body affected dystonia is organized in different localization 
like: a specific part of the body (e.g., writer’s cramp, blepharospasm). The segmental 
region affects two or more adjoining parts of the body. (e.g., cranial and cervical). 
Multifocal region involves two or more unrelated body parts (e.g., upper and lower 
limb, cranial and upper limb). The last body region affected by dystonia is a 
generalized form that affects most or all of the body (Albanese et al., 2011). 
Botulinum neurotoxins type A has shown to be an effective helpful alternative for a 
number of movement disorders being considered the first choice treatment for 
patients suffering from focal dystonia although it only minimizes the disease without 
treating it (Colosimo et al., 2012).  
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The way BoNT acts in the muscle is by temporarily weakening dystonic 
muscles, thereby allowing for a more normal posture and function of the patient.  
When injected in the muscle BoNT works inside the nerve terminals to block the 
release of the neurotransmitter acetylcholine which serves as a neurotransmitter 
that acts in initiating muscle contractions (Benecke, 2012, Troung et al., 2009). The 
effect of BoNT begins 3 - 12 days after an injection and the muscle weakness is 
typically lasting between 3–4 months (Jimenez-Shahed, 2011). At the intervals of 3 
months the injections effect are thought to reduce the risk of antibodies to the 
BoNT. The benefit of the treatment with BoNT results in the improvement of neck 
posture, muscle hypertrophy and pain reduction (Troung et al., 2009). 
The side effects of the BoNT are hypersensitivity reactions, injection site 
infections, bleeding or bruising, neck pain and weakness in muscles found nearby to 
the injection site as a result of toxin diffusion (Troung et al., 2009). One of the major 
problems of using BoNT as a treatment for dystonia is the immunoresistance 
development against the toxin. In the next section we are going to talk about this 
topic.  
Immunoresistance to BoNT-A 
Immunoresistance description 
 
As the use of BoNT in medical applications continues to increase the concern 
about immunoresistance to BoNT is also increasing. Immunoresistance to BoNT 
reduces significantly the efficiency of BoNT treatments and finally in some cases the 
treatment has no effect. Immunoresistance is the result of the natural occurring 
blocking antibodies (Zuber et al., 1993). These blocking antibodies are created by the 
human immunologic system in response to the presence of BoNT, their function is to 
neutralize and destroy the botulinum toxin from our body (Jankovic and Schwartz, 
1995). 
There are two types of immunoresistance: 
 Primary resistance 
 Secondary resistance 
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Primary resistance: 
Primary resistance refers to lack of response to the very first treatment of 
BoNT. This is extremely rare and is mainly due to a pre-existing immunization to 
botulinum toxin, that is people that had suffered from botulism previously. The 
natural response of the body is to generate blocking antibodies to botulinum toxin. 
After surviving the disease; these blocking antibodies remains in the body and these 
persons have already developed immunoresistance (Jankovic et al., 2003). 
 
Secondary resistance: 
Secondary resistance is the most likely cause of treatment failure. By 
definition, patients who developed secondary resistance have shown prior clinical 
response to BoNT. That is they have developed blocking antibodies to botulinum 
toxin after the medical treatment has started. This secondary resistance is 
responsible of losing the benefit of the treatment.  
The difference between primary resistance and secondary resistance is while 
in primary resistance the patient shows immunoresistance from the very first 
injection, in secondary resistance the patients have no problem with the first 
injections and show clinical response. As a consequence of these first injections the 
body starts creating the antibodies to fight BoNT-A. Consequently subsequent 
injections are less efficient. 
The clinical use of BoNT-A consist of the botulinum neurotoxin protein in 
combination with other non-toxic proteins. In addition to the toxin, the non-toxic 
proteins are also capable to generate antibodies production, thus creating an 
immunoresistance problem (DasGupta, 1994). More information about these 
proteins will be detailed in the section: Complexing proteins. 
 
Different brands of BoNT claims to have products generating less immunoresistance. 
An introduction to the three main manufactures today of BoNT and their products is 
presented below. 
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Brands of BoNT-A 
 
In this section we would like to explain the main differences between three 
BoNT-A drug brands: Xeomin, Botox and Dysport. They all contain the same 
toxin, but vary in terms of manufacturing and protein synthesis.  
To begin with, they all come from the same Clostridium botulinum bacteria 
strains, called the “Hall” strain  (Frevert and Dressler, 2010). 
The difference among them is the size of the protein. Botox, the most popular and 
known brand of all, contains all of the complexing proteins with a molecular weight 
of 900kDa. Dysport also contains complexing proteins of variable sizes between 
300kDa and 900kDa (Wenzel et al., 2007). The third brand, Xeomin, is free from 
complexing proteins and contains only active neurotoxin, which is 150kDa 
(Roggenkamper et al., 2006). In Table 2 is shown the main properties of the 
preparations of all three BoNT-A brands. Some studies suggested that it is 
complexing proteins, also called neurotoxin-associated proteins that may lead to the 
formation of neutralizing antibodies (Park et al., 2011). However one of the biggest 
problems of using Botox and Dysport is immunoresistance. More about 
complexing protein will be written in the following section. 
 
 
Table 2. Properties of different botulinum toxin preparations (Juwan,  et al., 2011). 
 
  
Brand name Botox Dyspot Xeomin 
Generic name OnabotulinumtoxinA AbobutulinumtoxinA IncobotulinumtoxinA 
Manufacturer Allergan Inc (USA) Ipsen Ltd (UK) 
Merz Pharmaceuticals GmbH 
(Germany) 
Serotype  A A A 
Complex size (kDa)  900 300-900 150 
Complexing proteins  Yes Yes No 
Specific neurotoxin 
activity (U/ng) 137 154 227 
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Factors causing immunoresistance 
Complexing proteins 
 
The commercial product of BoNT-A is the result of a sophisticate production 
process. This process is based on the manufacture of the botulinum toxin from the 
strains of the Clostridium botulinum bacteria, and the posteriori preparation of the 
toxin before it can be used as a commercial product. Different excipients might be 
added to the toxin in order to, for example, extend the shelf life (stability) of the 
product. During this process possible impurities can be obtained (The Management, 
Design and Operation of Microbiological Containment Laboratories, 2001). 
Furthermore non-toxic proteins are also formed and attached to BoNT-A. These 
proteins are known as complexing proteins and their function is not completely 
understood.  Figure 3 shows all the preparation processes.  
There are several suggestions about what could be the possible roles of the 
complexing proteins (Park et al., 2011).  At the very first it was proposed that they 
protect the botulinum toxin in the gastrointestinal tract from gastric pH extremes 
(Ohishi, 1977). However, in the medical applications, when toxin is injected in vitro, 
complexing proteins do not have any function and therefore are not necessary. 
Additionally, it was also hypothesized that they might play a role in limiting the 
diffusion of the toxin away from the injection area or they might enhance the 
stability of botulinum toxin (Aoki et al., 2006). Neither of this was confirmed. Several 
experiments were performed and no significant difference in diffusion or in stability 
of the toxin were seen between only neurotoxin (150kDa) and toxin complex 
(900kDa) (Frevert and Dressler, 2010). 
Although it seems that complexing proteins do not have a function in limiting 
diffusion or the stability of BoNT-A, it is conceivable that they are involved in the 
production of blocking antibodies. It was noticed that after the original Botox 
formulation was improved and contained fewer of complexing proteins, it reduced 
the risk of antibody formation by 6 times (Park et al., 2011).  Complexing proteins 
contain hemagglutinin (HA), which are lectins. It is known that lectin plays an 
important role in the immune system (Park et al., 2011).  In Figure 3 you can see the 
content of BoNT preparations. The procedure can be divided in three parts. In the 
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first one you separate botulinum toxin from the excipients (inactive substances of 
the medication), whereas at the next step you can separate BoNT from the 
complexing properties, that contains HA, known for its immunogenicity properties 
(Park et al., 2011). 
 
 
Figure 3. Composition of botulinum toxin preparation. Note: HA: Hemagglutinin; NHA, Non-
Hemagglutitnin (Park et al. 2011). 
 
In a clinical trial program in US, 12 of 1080 patients treated with botulin toxin 
without complexing proteins (brand known as Xeomin) developed blocking 
antibodies against the toxin. However, it is important to note, that all of these 
patients was treated earlier with botulin toxin with complexing proteins. It is highly 
possible that they have been already primed from previous treatment (Frevert and 
Dressler, 2010). In table 4 you can see the percentage of patients showing 
immunoresistance for each brand of BoNT-A in cervical dystonia. 
The immunoresistance for Xeomin is not stated, because it has been 
approved to treat cervical dystonia not a long time ago (2005 in Europa and 2010 in 
USA) and there are not any appropriate statistical studies available. However, 
immunogenicity of Xeomin was compared with Botox and Dyspot in New Zealand 
white rabbits. Interestingly, the results showed no antibodies formation with 
Xeomin, contrary to Botox and Dyspot that induced the formation of neutralizing 
antibodies. (Blümel et al., 2006) 
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Table 4. The percentage of people who get immunoresistancy after treatment for cervical 
dystonia. 
 
BoNT-A biological activity. 
 
An ELISA sandwich (see Elisa appendix) procedure was performed using the 
extracted antibodies from rabbit and guinea pigs treated with C. botulinum type A. 
The purpose of this procedure was to conclude the concentration of the 150kD 
neurotoxin in Botox, Dysport and Xeomin (Frevert, 2010) and to determine the 
highest specific neurotoxin activity, which serves as a parameter for the 
immunological quality of a BoNT drug (Troung et al., 2009).  In Xeomin the highest 
specific activity was 227 units/ng, Dysport had 154 units/ng and Botox with the 
lowest biologic activity of 137 units/ng.  (See table 2) 
The outcome of the experiment had shown that 100 units of Botox contain a 
concentration of 0.73 ng, Dysport - 0.65 ng and Xeomin contain 0.44 ng of BoNT type 
A (Pagan and Harrison, 2012) (See Table 5).  
 
Table 5. The concentration of 100 U of toxin after the ELISA sandwich experiment in the Botox, 
Dysport and Xeomin 
 
In Freverts paper  (Frevert, 2010) the authors proposal was that 0.44 ng neurotoxin 
in 100 units Xeomin is as potent as the 0.73 ng neurotoxin in 100 units Botox. The 
result suggests that Xeomin contains only active neurotoxin, whereas Botox is likely 
to contain denatured neurotoxin (Frevert, 2010). 
The presence of remaining denatured/inactive neurotoxin in Botox or Dysport 
can be associated with the manifestation of neurotoxin neutralizing antibodies in 
some patients. Another condition of supporting the previous statement is by looking 
at the amount of neurotoxin in Botox, which is estimated from the proportion of 
neurotoxin in the complex: the 150 kD neurotoxin found in Xeomin should be one-
sixth of the 900 kD complex. Thus 5ng (reported by Botox in the medical 
Brand name Botox Botox  old Dyspot Xeomin 
Immunoresistance 1.2 % 9.5% 3% Not stated 
Brand name Botox Dyspot Xeomin 
Concentration 0.73 ng 0.65 ng 0.44 ng 
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prescription) would be 5ng/6 = 0.83 ng), which is closely to the 0.73 ng proved in Dr. 
Freverts analysis. 
3. Discussion 
 
Nowadays BoNT-A is used more and more in medical applications related to the 
nervous system and movement disorders. BoNT-A is not the cure of the disease but 
is helping in minimizing the symptoms. By this the life of the patient is better and the 
quality of life improved. Unfortunately BoNT-A has a limited time effect in the body; 
therefore the treatment should be repeated periodically (Jimenez-Shahed, 2011). 
Human immune system plays a role here because it considers BoNT-A as a pathogen 
and therefore starts the natural occurring defense reaction through blocking agents 
and antibodies. The function of the last ones is to neutralize and eliminate the toxin 
presence in our body and this is indeed a challenge in the medical field.  
Body immunoresistance against BoNT-A product is the one of the main 
reasons of treatment failure. When a patient develops blocking antibodies the effect 
of BoNT-A is minimized, and finally eliminated. In order to minimize the 
immunoresistance effect manufacters work with the BoNT-A protein composition 
and protein synthesis. The higher the purity of BoNT-A and the lower the amount of 
complexing proteins the lower the immunoresistance risk. It has been suggested that 
complexing proteins also known as non-toxic proteins that are attached to the toxic 
BoNT-A protein, are responsible for the immunoresistance response (Park et al., 
2011).   
At the same time that BoNT-A medical use is increasing the concern about 
immunoresistance is also increasing. Different commercial products claim different 
degrees of tolerance by the immune system. The new brands work in the synthesis 
of pure active toxin with no complexing proteins. That is the case of Merz 
Pharmatheutical, with Xeomin product. Merz claims (Frevert, 2010) that due to the 
purity of its product the immunoresistance response to the treatment is minimized.  
 
What seems to be clear is that the purity of the BoNT-A proteins plays an essential 
role in the immunoresistance response. Other commercial brand, Botox have 
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reformulated their product in order to make it more tolerant. That is by modifying 
the composition of the protein by removing the complexing proteins in order to 
minimize the risk of immunoresistance.  
The different producers of BoNT-A give no standardized information about 
biological activity. That means there is no standard and common method for the 
measurement of the biological activity of the different products. This makes it 
difficult to find a possible and objective scientific study since a lot of the available 
information is directly coming from the private industry or from public scientific 
studies funded by them. Results published by the industry must be taken with 
cautiousness even though there is some scientific reasoning behind them. It is clear 
that the private industry is aware that the present formulations must be improved in 
order to minimize the immunoresistance response. Old brands like Botox and 
Dysport change their product formulations to make them more efficient and less 
immunoresistant.  A new BoNT-A brand, Xeomin, claims that their formula do not 
have any immunogenicity. Unfortunately, it has been approved for the treatment of 
cervical dystonia only a few years ago in USA and therefore there are no strong 
statistical studies that clearly support this statement.  For some patients it takes 
several years to develop immune response. 
4. Conclusions 
 
It has been demonstrated that BoNT-A application in medical treatment for 
cervical dystonia improves the symptoms and increase the patient’s quality of life. 
This treatment has a strong drawback: toxin immunoresistance response in the 
human body. From our study we can conclude that the immunoresistance is 
generally related to the purity of the toxin protein and with the complexing proteins 
present in the product. Although the highly pure BoNT-A reduces immunoresistance, 
it has not been proved that immunoresistance can be completely avoided. Further 
work must be done in the direction of minimizing immunoresponse in the medical 
use of BoNT-A. 
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7. Appendix  
Appendix 1. Toxicon publication: Instructions for authors. 
 
Language  
Paper should be written in good English (American or British usage is 
accepted, but not a mixture if these). 
 
Abstract  
A concise and factual abstract is required. The abstract should state briefly 
the purpose of the research, the principal results and major conclusions. An abstract 
is often presented separately from the article, so it must be able to stand alone. For 
this reason, References should be avoided, but if essential., then cite the author(s) 
and year(s). Also, non-standard or uncommon abbreviations should be avoided, but 
if essential they must be defined at their first mention in the abstract itself.  
 
Keywords  
Immediately after the abstract, provide a maximum of 6 keywords, using 
American spelling and avoiding general and plural terms and multiple concepts 
(avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations 
firmly established in the field may be eligible. These keywords will be used for 
indexing purposes.  
 
Acknowledgements  
Collate acknowledgements in a separate section at the end of the article 
before the references and do not, therefore, include them on the title page, as a 
footnote to the title or otherwise. List here those individuals who provided help 
during the research (e.g., providing language help, writing assistance or proof 
reading the article, etc.).  
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Tables  
Number tables consecutively in accordance with their appearance in the text. 
Place footnotes to tables below the table body and indicate them with superscript 
lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that 
the data presented in tables do not duplicate results described elsewhere in the 
article.  
 
Reference style  
Text: All citations in the text should refer to:  
1. Single author: the author's name (without initials, unless there is ambiguity) and 
the year of publication. 
2. Two authors: both authors' names and the year of publication. 
3. Three or more authors: first author's name followed by 'et al.' and the year of 
publication.  
Example: 
Reference to the journal publication: 
 
Goschel, H., Wohlfarth, K., Frevert, J., Dengler, R., Bigalke, H., 1997. Botulinum A 
toxin therapy: neutralizing and non-neutralizing antibodies therapeutic 
consequences. Exp. Neurol. 147, 96–102. 
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Appendix 2. Neurotransmitters 
 
Neurotransmitters are molecules secreted by the neurons at synapses that 
diffuse a very short distance to bind to receptors on the target cells. In figure 5 this 
process is shown. Acetylcholine is an important neurotransmitter (see figure 4) of 
the nervous system functions. Muscle stimulation, memory formation and learning 
are processes where acetylcholine is present (Vanhoutte et al., 1986) 
 
 
Figure 4. Chemical structure of acetylcholine. 
 
Acetylcholine is found in the neuromuscular junction of vertebrates. BoNT disrupt 
the neurotransmission of acetylcholine. Intoxication of BoNT to humans can be fatal 
because muscle required for breathing fail to contract when acetylcholine release is 
blocked. 
 
 
 
Figure 5.  A neuron synapse with the synaptic vesicle containing acetylcholine. Since BoNT is blocking 
the release of the acetylcholine, cell signaling is stopped. 
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Appendix 3. SNARE proteins 
 
Chemical synaptic transmission or neurotransmission is essential for cell to 
cell communication. In the living cells, membrane fusion is mediated via a specialized 
set of proteins present in opposing bilayers. These proteins are called SNARE 
proteins. They are responsible for the neurotransmitter acetylcholine release from 
the nerve terminal to the synaptic cleft.  
There are two kinds of SNARE proteins: v-SNARE (vesicle-SNARE) that is 
located on the vesicle membrane (Sollner et al., 1993b) and t-SNARE (target-SNARE) 
that is located on the target membrane. SNARE complex contains three proteins: 
VAMP (vesicle-associated membrane protein) syntaxin 1, and SNAP-25 (synapto- 
somal-associated protein of 25 kDa). VAMP (Trimble et al., 1988) is located on the 
vesicle and therefore is v-SNARE and syntaxin (Bennett et al., 1992) with SNAP-25 
(Oyler et al., 1989) are anchored on the membrane and are classified as t-SNARE. 
They all form the crystal structure of the neuronal SNARE core complex. It has been 
shown that the complex contains a coil of syntaxin, a coil of VAMP, and two coils of 
SNAP-25: SNAP-25 amino-terminal helix, and SNAP-25 carboxy-terminal helix (Sutton 
et al., 1998). In the figure 6 can be seen the structure of SNARE complex. As it was 
mentioned before VAMP protein is anchored to the vesicle membrane and syntaxin 
and SNAP-25 is attached to the plasma membrane. 
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Figure 6. The complex of the SNARE proteins. Complex contains four helices: blue - VAMP, red-
syntaxin, green-SNAP-25 amino-terminal helic and SNAP-25 carboxy – terminal helix.  VAMP protein is 
integrated on the vesicle membrane and syntaxin with SNAP-25 helices are located on the plasma 
membrane.    
The ability of botulinum and tetanus neurotoxins to inhibit 
neurotransmission was used as a tool to study SNARE proteins and their mode of 
action. Botulinum and tetanus toxins cleave the one of the protein of the SNARE 
complex that leads to SNARE inactivation that prohibits the fusion of the cell 
membrane and vesicle. (Pellizzari et al., 1999).  
The understanding of synaptic vesicle membrane fusion requires a lot of 
biochemical and structural knowledge about SNARE proteins. It is not our intention 
to explain in details how neurotransmitters are released from the nerve terminal to 
the synaptic cleft. Each step of the model pathway explained below involves the 
action of additional regulatory factors that will not be mentioned. During the fusion 
two SNAREs: v-SNARE and t-SNARE bind together and forms a bundle. As it can be 
seen in the figure 7, initially all the proteins from the SNARE complex are unbound to 
each other. When the vesicle arrives, the nucleation of the ternary complex starts. 
The change in the calcium concentration brings v-SNARE and t-SNARE together, 
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called zippering. In this process v-SNARE get in to the contact with SNAP-25 and 
syntaxin and form a coiled bundle what brings the vesicle and plasma membrane 
into the contact. Zipping disrupts the lipid bilayer structure that causes hemifusion. 
Hemifusion is followed by complete fusion that opens fusion pores. When the pores 
widens neurotransmitters are released from the vesicle to the synaptic cleft.  (Lin 
and Scheller, 2000, Nelson and Cox, 2008)  
 
Figure 7. The function mechanism of SNARE complex in neurotransmitter release. In the relax mode v-
SNARE is unbound to t-SNARE. The nucleation brings both SNAREs into the contact. The increase of 
calcium induces zippering that causes tension on lipid bilayer. In the next step hemifusion starts 
followed by complete fusion that opens pore and neurotransmitters can leave the vesicle (Lin and 
Scheller, 2000, Nelson and Cox, 2008).  
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Appendix 4. Immune system 
 
The immune system is a complex mechanism, which has the ability to 
respond to substances called antigens that are recognized as foreign attackers for 
our body (Guyton and Hall, 2005). 
The consistence of immune system is of several types of cells and proteins that 
differentiate each other by the activity in fighting foreign invaders. 
The first part of the immune system that encounters attackers such as 
bacteria is a group of proteins that forms the basis for a particular system called the 
innate immunity (Litman et al., 2005). These proteins are found freely in the blood 
and can rapidly reach the site of an invasion where they can react directly with 
antigens. This process of developed immunity is the basis of vaccination. The innate 
system is found in all plants and animals (Janeway et al., 2001). If the invaders 
successfully escape the innate response, a second immune system called adaptive 
immune system is activated by the innate immunity and acts as a barrier to the 
pathogen (Mayer, 2006). The immune system adjusts its response during an 
infection to improve the detection of the pathogen. This improved response is then 
remembered after the pathogen has been eliminated, in the form of an 
immunological memory.  
The immunological memory prepares the adaptive immune system to act 
faster and stronger each time this pathogen is present. The adaptive system is 
retained only by the vertebrates (Mayer, 2006). The innate immunity contains white 
blood cells called leukocytes. There are five different types of leukocytes 
(phagocytes, mast cells, eosinophils, basophils, and natural killer cells) which 
derivate from a multipotent cell in the bone marrow (Alberts et al. 2002) (See figure 
8). The leukocytes have many things in common, but they are all distinct in form and 
function inside the immune system by identifying and eliminating pathogens that 
cause infection (Janeway et al., 2001). The immune response occurs when bacteria 
or any other cause, damages tissues in our body. The damaged cells release 
chemicals like histamine that generate the blood vessels to leak fluid into the tissues, 
causing swelling. The chemicals attract the white blood cells called phagocytes that 
"eat" microorganisms and damaged cells. (Firestein, 2007). 
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Mast cells live in connection tissues and mucous membranes and their role is to 
regulate the inflammatory response (Krishnaswamy et al., 2006). 
Eosinophils and basophils are phagocytes that travel throughout the body in hunting 
invaders pathogens. They secrete chemical mediators that are involved in defending 
against parasites and play a role in allergic reactions (Kariyawasam and Robinson, 
2006). Natural killers cells role is to attack and destroy tumor cells or cells that have 
been infected by viruses (Middleton et al., 2002). 
The adaptive immune system contain special type of leukocytes cells called 
lymphocytes which, like all blood cells, originate from multipotent cells in the bone 
marrow (Alberts et al., 2002). Lymphocytes that migrate from the bone marrow to 
the thymus, mature into T cells while lymphocytes that mature in the bone marrow 
develop as B cells (Campbell and Reece, 2007), (See Fig. 6). T cells attack antigens 
directly and help control the immune response. They also release chemicals, known 
as cytokines, which coordinate the overall immune response (Goronzy and Weyand, 
2007). B cells are best known for making antibodies that will bind to an antigen and 
marks the antigen for destruction by other immune system cells (Campbell and 
Reece, 2007). 
 
 
 
 
  
    Figure 8. The Human immune system composition in the blood and lymph 
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Appendix 5. ELISA 
 
Elisa sandwich overview: 
Enzyme-linked immunosorbent assay (ELISAs) is a biochemical technique 
used in determining and measuring the quantity of substances such as peptides, 
proteins, antibodies and hormones. 
There are two types of the ELISA technique, depending on the purpose of the 
experiment: 
The first technique is called Direct ELISA and the purpose is to detect the presence of 
a particular antigen in a sample. The second technique, called Indirect ELISA is to 
determine the presence of a specific antibody in the sample. The techniques 
mentioned in this project is for determining the concentration of the 150kD 
neurotoxin and is so called sandwich ELISA techniques. The principle of this 
procedure is to measure the amount of antigen (e.g. the neurotoxin) between two 
layers of antibodies.  
The method involves one antibody that is bound to a 96-plate well. The antigen is 
added and bound to the antibody. Unbound products are then wash away and a 
labeled secondary antibody also called the detection antibody is added, therefore 
completing the “sandwich”. The assay is quantified by measuring the amount of 
labeled secondary antibody through the use of a colorimetric substrate (Overview of 
ELISA, 2012). 
 
 
 
